Floatz logo

NA 831

Alzheimer Dementia

Biomed Industries, Inc.Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the Alzheimer Dementia cohort.

Asset / SponsorPhaseRating
L-HUPERZINE A
Wanbangde Pharmaceutical Group Co., LTD
Phase 2/3BB
FALLYPRIDE
Duke University
Phase 4BB
1H-3-BENZAZEPIN-7-OL, 5-(7-BENZOFURANYL)-8-CHLORO-2,3,4,5-TETRAHYDRO-3-METHYL-, (5S)-
Duke University
Phase 4BB
ALLOPREGNAN-3.ALPHA.-OL-20-ONE
University of Arizona
Phase 2B
Contraloid
Charite University, Berlin, Germany
Phase 1CCC

View all 11 →

Same molecule, other indications

NA 831 is also rated in:

Cognitive DisorderDormant
B
Indicative ·
57 / 100
View asset →
cognitive disorderDormant
B
Indicative ·
57 / 100
View asset →
vascular dementiaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →